U.S. Judge Orders Watson Executive to Comply With FTC Subpoena

A Watson Pharmaceuticals Inc. executive has been ordered by a federal judge to comply with a U.S. Federal Trade Commission subpoena in a patent case involving Cephalon Inc.’s sleep-disorder drug Provigil.

Paul Bisaro, president and chief executive officer of Corona, California-based Watson, a generic-drug maker, “has failed to demonstrate” that the subpoena “would be burdensome at all, let alone unduly so,” U.S. District Judge Colleen Kollar-Kotelly wrote in her opinion.

To contact the reporter on this story: Jeff Bliss in Washington jbliss@bloomberg.net

To contact the editor responsible for this story: Mark Silva in Washington at msilva34@bloomberg.net

Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.